SeromaNCT00968318
Excision of Strip of Deep Fascia to Reduce Seroma Formation and Extrusion of Tissue Expanders
A study testing Excision of strip of deep fascia in people with Seroma, run by Cairo University at 1 site in Egypt.
Trial summary
Tissue expansion has enjoyed a wide range of applications since the technique was popularized in the latter quarter of the last century. During the expansion process, subcutaneous fat liquefies, skin becomes thinner, muscles atrophy, blood inflow increases, and lymphatics get occluded. Read more about this study
- Who is it for?
- Ages 12 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Seroma
- What is being tested?
- Excision of strip of deep fascia
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 56 participants
- Where
- 1 siteEgypt
- Study dates
- May 2006to Nov 2008
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 55 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- Tissue expanders in neck and limbs.
Who cannot join
- Tissue expanders in other parts of the body.
Trial locations and contacts
1 site in 1 country.
About this study
Tissue expansion has enjoyed a wide range of applications since the technique was popularized in the latter quarter of the last century. During the expansion process, subcutaneous fat liquefies, skin becomes thinner, muscles atrophy, blood inflow increases, and lymphatics get occluded. All these factors predispose to seroma formation and implant extrusion.
A similar problem occurred with lymphoedema patients, and one of the lines of treatment was creation of a connection to the deep lymphatics to facilitate absorption of accumulated fluid. The same principle is to be extrapolated to patients having tissue expanders inserted in the neck and limbs and its effect is to be noted on the incidence of seroma .
Read the detailed description
The techniques of tissue expansion have been used for many years to expand normal skin adjacent to the site of a defect. Initially described by Neuman in 1953, it gained widespread popularity in the eighth decade of the last century after the work of Radovan, and has been progressively popular since.
The physiology of prolonged tissue expansion was not just a matter of stretching skin, but the actual formation of additional new skin which had all the attributes of the original tissue. Austad et al. postulated that tissue expansion caused a decrease in cell density in the basal layer of the skin and that cell density might regulate skin mitotic activity. A lower cell density resulted in a greater cell proliferation, resulting in growth of additional skin. Inflation of the tissue expander was found to cause a threefold elevation of epidermal mitotic activity within 24 hours, followed by a gradual return to normal baseline over 2 to 5 days. Conversely, deflation of the expander caused a transient decrease in epidermal mitotic activity. The increase in mitosis returned to normal 4 weeks after expansion.
The dermis and subcutaneous tissues were thinned as a result of tissue expansion leading to an overall decrease in tensile strength of the expanded skin (5-7) and this persisted 36 weeks after expansion. The subcutaneous layer of fat was intolerant to stretching causing significant thinning. With faster expansion, fat necrosis could be seen. Pressure necrosis on subcutaneous fat led to liquefaction and seroma formation. With progression of expansion compression of superficial lymphatics resulted in their occlusion and lymph accumulation. Furthermore, the muscle layer in pigs, which was similar to the platysmal layer in humans, tended to atrophy with maximal expansion. As expansion proceeded, there was an increase in the number and size of the blood vessels within flaps supplied by random-pattern vessels and, if present, axial vessels. These changes corresponded to the demonstrated increase in blood flow to expanded flaps. In the study by Saxby this lead to surviving lengths after expansion being 50 percent greater than the delayed controls, and nearly 150 percent greater than comparable flaps raised acutely.
These histologic and physiologic findings would explain the high incidence of seroma formation with tissue expanders especially those inserted in areas rich in subcutaneous fat, such as the neck and limbs. During the expansion process, subcutaneous fat liquefies, skin becomes thinner, muscles atrophy, blood inflow increases, and lymphatics get occluded. All these factors when coupled with the fact that mere presence of a foreign body incites fluid exudation would be a frank invitation for seroma formation and implant extrusion.
Reported rates of seroma varied in the literature between 5-18%. Its effect ranged from minor complications that that did not interrupt the expansion process or require any operative intervention (32%) up to major complications that required additional operative intervention (12%).
Opinions differed between authors regarding seroma prevention. Several authors omit use of drainage procedures to prevent infection. Others use closed suction drains but there was an increased risk of infection; and seromas tended to occur following their removal.
External filling ports might drain seromas through the entry port, but at the risk of increased infection rates (19). Over inflation of the expanders to obliterate any dead space came with the risk of overlying skin ischemia and necrosis.
As a projection to the hypothesis of Thompson on lymphoedema management, this study was performed to find the effect of opening new drainage channels between the superficial and deep lymphatics on the incidence of seroma formation.
- Conditions
- Seroma
- Being tested
- Excision of strip of deep fascia
- Keywords
- Tissue expander, seroma, extrusion, lymphatics, deep fascia, Rate of seroma formation after excision of strip of deep fascia
- Medical subject headings
- Seroma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Excision of strip of deep fasciaProcedure or surgery
operative technique to excise deep fascia.
| Study group | Role | What they receive |
|---|---|---|
| Rate of seroma formation | Other | Excision of strip of deep fascia was assessed regarding the rate of seroma formation with tissue expander insertion Receives: Procedure: Excision of strip of deep fascia |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reduction of seroma formation
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Aug 2009 (estimated)
- Study startMay 2006
- Primary completionSep 2008
- Study completionNov 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SeromaStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 56 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Investigators
- Adel Wilson, MD, Principal investigator, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00968318
- Sponsor's protocol ID
- Reduce seroma with expanders
- Status last verified
- Aug 2009
- First submitted
- 27 Aug 2009
- Last updated
- 28 Aug 2009
- Results posted
- No
- Data monitoring committee
- No
Publications
Adler N, Dorafshar AH, Bauer BS, Hoadley S, Tournell M. Tissue expander infections in pediatric patients: management and outcomes. Plast Reconstr Surg. 2009 Aug;124(2):484-489. doi: 10.1097/PRS.0b013e3181adcf20.
PubMed 19644263
Study at a glance
From the registry record, last updated by the sponsor on 28 Aug 2009. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Excision of Strip of Deep Fascia to Reduce Seroma Formation and Extrusion of Tissue Expanders
- ClinicalTrials.gov ID
- NCT00968318
- Acronym / sponsor ID
- Reduce seroma with expanders
- Conditions
- Seroma
- Keywords
- Tissue expander, seroma, extrusion, lymphatics, deep fascia, Rate of seroma formation after excision of strip of deep fascia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 56 participants (actual)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- May 2006
- Primary completion
- Sep 2008 (actual)
- Study completion
- Nov 2008 (actual)
- First posted
- 28 Aug 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Tissue expansion has enjoyed a wide range of applications since the technique was popularized in the latter quarter of the last century. During the expansion process, subcutaneous fat liquefies, skin becomes thinner, muscles atrophy, blood inflow increases, and lymphatics get occluded. All these factors predispose to seroma formation and implant extrusion.
A similar problem occurred with lymphoedema patients, and one of the lines of treatment was creation of a connection to the deep lymphatics to facilitate absorption of accumulated fluid. The same principle is to be extrapolated to patients having tissue expanders inserted in the neck and limbs and its effect is to be noted on the incidence of seroma .
Detailed description
The techniques of tissue expansion have been used for many years to expand normal skin adjacent to the site of a defect. Initially described by Neuman in 1953, it gained widespread popularity in the eighth decade of the last century after the work of Radovan, and has been progressively popular since.
The physiology of prolonged tissue expansion was not just a matter of stretching skin, but the actual formation of additional new skin which had all the attributes of the original tissue. Austad et al. postulated that tissue expansion caused a decrease in cell density in the basal layer of the skin and that cell density might regulate skin mitotic activity. A lower cell density resulted in a greater cell proliferation, resulting in growth of additional skin. Inflation of the tissue expander was found to cause a threefold elevation of epidermal mitotic activity within 24 hours, followed by a gradual return to normal baseline over 2 to 5 days. Conversely, deflation of the expander caused a transient decrease in epidermal mitotic activity. The increase in mitosis returned to normal 4 weeks after expansion.
The dermis and subcutaneous tissues were thinned as a result of tissue expansion leading to an overall decrease in tensile strength of the expanded skin (5-7) and this persisted 36 weeks after expansion. The subcutaneous layer of fat was intolerant to stretching causing significant thinning. With faster expansion, fat necrosis could be seen. Pressure necrosis on subcutaneous fat led to liquefaction and seroma formation. With progression of expansion compression of superficial lymphatics resulted in their occlusion and lymph accumulation. Furthermore, the muscle layer in pigs, which was similar to the platysmal layer in humans, tended to atrophy with maximal expansion. As expansion proceeded, there was an increase in the number and size of the blood vessels within flaps supplied by random-pattern vessels and, if present, axial vessels. These changes corresponded to the demonstrated increase in blood flow to expanded flaps. In the study by Saxby this lead to surviving lengths after expansion being 50 percent greater than the delayed controls, and nearly 150 percent greater than comparable flaps raised acutely.
These histologic and physiologic findings would explain the high incidence of seroma formation with tissue expanders especially those inserted in areas rich in subcutaneous fat, such as the neck and limbs. During the expansion process, subcutaneous fat liquefies, skin becomes thinner, muscles atrophy, blood inflow increases, and lymphatics get occluded. All these factors when coupled with the fact that mere presence of a foreign body incites fluid exudation would be a frank invitation for seroma formation and implant extrusion.
Reported rates of seroma varied in the literature between 5-18%. Its effect ranged from minor complications that that did not interrupt the expansion process or require any operative intervention (32%) up to major complications that required additional operative intervention (12%).
Opinions differed between authors regarding seroma prevention. Several authors omit use of drainage procedures to prevent infection. Others use closed suction drains but there was an increased risk of infection; and seromas tended to occur following their removal.
External filling ports might drain seromas through the entry port, but at the risk of increased infection rates (19). Over inflation of the expanders to obliterate any dead space came with the risk of overlying skin ischemia and necrosis.
As a projection to the hypothesis of Thompson on lymphoedema management, this study was performed to find the effect of opening new drainage channels between the superficial and deep lymphatics on the incidence of seroma formation.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Rate of seroma formation | Other | Procedure: Excision of strip of deep fasciaExcision of strip of deep fascia was assessed regarding the rate of seroma formation with tissue expander insertion |
Who may qualify
- Ages
- 12 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (1 listed)
- Tissue expanders in neck and limbs.
Key exclusion criteria (1 listed)
- Tissue expanders in other parts of the body.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Excision of strip of deep fasciaoperative technique to excise deep fascia. | Procedure or surgery | Rate of seroma formation |
Primary outcome
Reduction of seroma formation
Time frame: 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Aug 2009.
- Background: PubMed 19644263Adler N, Dorafshar AH, Bauer BS, Hoadley S, Tournell M. Tissue expander infections in pediatric patients: management and outcomes. Plast Reconstr Surg. 2009 Aug;124(2):484-489. doi: 10.1097/PRS.0b013e3181adcf20.
Related trials for Seroma
Recruiting
Primary Sac Abandonment and Distal Sac Fixation vs Complete Sac Dissection for Inguinoscrotal Hernias
Seroma, Inguinal Hernias
Recruiting
Comparison of Two Surgical Techniques for Indirect Inguinal Hernia Repair
Indirect Inguinal Hernia
Not yet recruiting
Topical Tranexamic Acid Spray Versus No Spray on Postoperative Outcomes Following Mesh Repair of Umbilical Hernia
Umbilical Hernia Repair
Recruiting
Hernia Sac Flap Coverage of Mesh in Bony-Edged Ventral Hernia Repair
Incisional Hernia, Abdominal Hernia
RecruitingPhase 4
The Effect of Local Application of Tranexamic Acid Versus Placebo on Postoperative Complications in Plastic Surgery
Surgical Complication
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Adel Wilson, MD principal investigator
Cairo University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Excision of strip of deep fascia in people with Seroma, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Aug 2009. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reduction of seroma formation (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00968318, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Aug 2009.